Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing

Goodwin, Daryn; Rathi, Vivek; Conron, Matthew; Wright, Gavin

doi:10.1016/j.jtho.2021.03.018

Cited by 32 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is still a long way to go from discovery and research maturation to clinical application. In addition, clinical sequencing of patients with advanced lung cancer can be used to determine which oncogenes are mutated and is a more accurate diagnostic and prognostic tool that can better guide management and predict outcomes [ 132 ]. It can be used not only for effective targeted therapy but also to collect more clinical data for future studies.…”

Section: Discussionmentioning

confidence: 99%

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

Wei

Chai

et al. 2022

IJMS

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death worldwide. miR-199a, which has two mature molecules: miR-199a-3p and miR-199a-5p, plays an important biological role in the genesis and development of tumors. We collected recent research results on lung cancer and miR-199a from Google Scholar and PubMed databases. The biological functions of miR-199a in lung cancer are reviewed in detail, and its potential roles in lung cancer diagnosis and treatment are discussed. With miR-199a as the core point and a divergence outward, the interplay between miR-199a and other ncRNAs is reviewed, and a regulatory network covering various cancers is depicted, which can help us to better understand the mechanism of cancer occurrence and provide a means for developing novel therapeutic strategies. In addition, the current methods of diagnosis and treatment of lung cancer are reviewed. Finally, a conclusion was drawn: miR-199a inhibits the development of lung cancer, especially by inhibiting the proliferation, infiltration, and migration of lung cancer cells, inhibiting tumor angiogenesis, increasing the apoptosis of lung cancer cells, and affecting the drug resistance of lung cancer cells. This review aims to provide new insights into lung cancer therapy and prevention.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

Wei

Chai

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Other studies using different gene panels or clinical cohorts demonstrated similar utility to this approach, 45–51 and confirmed worse outcomes in patients with genomically similar tumors. 21 These analyses are summarized in Table 1 .…”

Section: Limitations Of Pathologic Approaches and Incorporation Of Molecular Analysesmentioning

confidence: 99%

“…Two patients with inferred metastases had shared mutations; two patients had shared driver alterations. Goodwin et al, 2021 21 40 cases of pts treated curatively for two putative primaries with similar histopathology. Targeted NGS panel (Ion Ampliseq Colon and Lung Cancer Panel V2 and RNA-fusion panel).…”

Section: Limitations Of Pathologic Approaches and Incorporation Of Molecular Analysesmentioning

confidence: 99%

“…The presence of a histologically presumed intrapulmonary metastasis carries a 10–15% decrease in 5-year survival, 17–21 whereas multiple primaries are not necessarily associated with worse outcomes. 21 , 22 Similarly, as discussed, the appropriate classification of MLTs as distinct primaries or IPMs carries important management implications. Misclassification of distinct early-stage lung primaries as T3 or T4 IPMs can lead to exposure to the toxicities of adjuvant platinum-based chemotherapy with no clinical benefit and potential harm; 10 upstaging contralateral nodules as IPMs can also prevent patients from receiving appropriate definitive local therapies.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers

Zhang¹

2021

LCTT

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often require adjuvant chemotherapy or may in fact be incurable stage IV lesions. Conversely, MLTs that represent distinct primaries have a better prognosis and may be overtreated if inappropriately classified as related secondaries. Historically, pathologic and radiographic criteria were used to distinguish between primary and secondary MLTs; however, the advent of genomic profiling has demonstrated limitations to these historic classification systems. In this review, we discuss the use of molecular profiling to distinguish between primary and secondary lung cancers, with a focus on the insights gleaned from whole exome sequencing (WES) analyses. While WES is not yet feasible in routine clinical practice, WES studies have helped elucidate the clonal relationship between primary and secondary lung cancers and provide important context for the application of targeted sequencing panel-based analyses.

show abstract

“…Due to this inconclusiveness, molecular science is emerging as a means to provide definitive diagnoses. 6 , 9 , 10 Theoretically, the pathogenesis of lung cancer is intricately linked to molecular variations that give rise to diverse tumors types and distinct hallmarks. 11 Thus, the discrimination hinges on the molecular heterogeneity within MPLCs and the homogeneity within IPMs.…”

Section: Introductionmentioning

confidence: 99%

Towards the molecular era of discriminating multiple lung cancers

Wang¹,

Yuan²,

Jiang³

et al. 2023

eBioMedicine

View full text Add to dashboard Cite

Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing

Cited by 32 publications

References 36 publications

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer

The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers

Towards the molecular era of discriminating multiple lung cancers

Contact Info

Product

Resources

About